all ( 25 results found)
ADM
DHPC - Risk of secondary malignancy of T-cell origin in CD19- or BCMA-directed CAR T-cell therapies
DHPC communication - restriction of use in neonates as concentration of the excipient, propylene glycol, exceeds recommended threshold
DHPC enzalutamide test interference leading to falsely elevated digoxin plasma levels
EpiPen® Healthcare Professional Letter
EpiPen® Healthcare Professional Letter
Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation
Fluoroquinolones DHPC_HPRA_FINAL vs2 30-05-23
IE Adcortyl Discontinuation Letter June 2025
Infanrix Hexa - DHPC
Product Recall Palmeux - pharmacy letter
Product Recall Palmeux - pharmacy letter
Product Recall Palmeux - pharmacy letter
Product Recall Palmeux- pharmacy letter
Risperidone 1mg per ml OS-Risk of medication errors leading to accidental overdoses in children and adolescents
Test
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Topiramate: New restrictions to prevent exposure during pregnancy
Veoza - 45mg film-coated tablets_DHPC January 2025
Zadenvi HCP Letter
Zolgensma (onasemnogene abeparvovec): Important Safety Information
